Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

Core Viewpoint - Kamada Ltd. is set to release its financial results for the second quarter and first half of 2024 on August 14, 2024, prior to the opening of U.S. financial markets [1] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of marketed products and a strong presence in the specialty plasma-derived field [3] - The company has six FDA-approved plasma-derived biopharmaceutical products, including KEDRAB®, CYTOGAM®, WINRHO SDF®, VARIZIG®, HEPAGAM B®, and GLASSIA®, along with KAMRAB® and KAMRHO (D)® [3] - Kamada distributes its products in over 30 countries, leveraging its expertise in the Israeli market to distribute more than 25 pharmaceutical products from international manufacturers [3] - The company has added eleven biosimilar products to its distribution portfolio in Israel, expected to launch by 2028, pending regulatory approvals [3] - Kamada owns an FDA-licensed plasma collection center in Beaumont, Texas, specializing in hyper-immune plasma collection [3] Financial Communication - Management will host a conference call on August 14, 2024, at 8:30 AM Eastern Time to discuss the financial results and answer questions from shareholders and interested parties [2]